Maxigen Biotech Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Maxigen Biotech.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Biotechs earnings growth	48.4%
Revenue growth rate	n/a
Future return on equity	n/a
Analyst coverage	None
Last updated	n/a

Recent future growth updates

No updates

Recent updates

Maxigen Biotech's (TWSE:1783) Earnings Are Of Questionable Quality

Mar 28

Maxigen Biotech Inc. (TPE:1783) Is Yielding 2.3% - But Is It A Buy?

Apr 22

We Think You Should Be Aware Of Some Concerning Factors In Maxigen Biotech's (TPE:1783) Earnings

Apr 01

Maxigen Biotech Inc.'s (TPE:1783) Stock Has Seen Strong Momentum: Does That Call For Deeper Study Of Its Financial Prospects?

Mar 16

The Maxigen Biotech (TPE:1783) Share Price Has Gained 22% And Shareholders Are Hoping For More

Feb 23

Can Maxigen Biotech (TPE:1783) Continue To Grow Its Returns On Capital?

Feb 02

Tread With Caution Around Maxigen Biotech Inc.'s (TPE:1783) 3.4% Dividend Yield

Jan 10

Declining Stock and Decent Financials: Is The Market Wrong About Maxigen Biotech Inc. (TPE:1783)?

Dec 14

If You Had Bought Maxigen Biotech's (TPE:1783) Shares Five Years Ago You Would Be Down 13%

Nov 22

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Maxigen Biotech has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

TWSE:1783 - Analysts future estimates and past financials data (TWD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
6/30/2024	609	147	149	173	N/A
3/31/2024	606	150	178	201	N/A
12/31/2023	622	166	149	171	N/A
9/30/2023	638	191	174	192	N/A
6/30/2023	641	192	232	249	N/A
3/31/2023	624	163	219	235	N/A
12/31/2022	604	139	254	268	N/A
9/30/2022	581	110	222	236	N/A
6/30/2022	557	99	183	203	N/A
3/31/2022	524	87	132	153	N/A
12/31/2021	512	88	102	118	N/A
9/30/2021	494	94	124	139	N/A
6/30/2021	470	76	117	124	N/A
3/31/2021	465	75	93	100	N/A
12/31/2020	458	63	63	75	N/A
9/30/2020	447	50	28	59	N/A
6/30/2020	452	58	47	69	N/A
3/31/2020	463	64	51	75	N/A
12/31/2019	452	60	71	94	N/A
9/30/2019	434	60	72	77	N/A
6/30/2019	427	58	50	72	N/A
3/31/2019	413	55	117	138	N/A
12/31/2018	428	57	150	171	N/A
9/30/2018	445	53	160	178	N/A
6/30/2018	438	43	151	164	N/A
3/31/2018	441	28	N/A	107	N/A
12/31/2017	428	16	N/A	51	N/A
9/30/2017	421	16	N/A	22	N/A
6/30/2017	403	7	N/A	40	N/A
3/31/2017	366	-5	N/A	47	N/A
12/31/2016	336	-12	N/A	35	N/A
9/30/2016	297	-44	N/A	18	N/A
6/30/2016	276	-49	N/A	-45	N/A
3/31/2016	269	-61	N/A	-62	N/A
12/31/2015	261	-63	N/A	-110	N/A
9/30/2015	251	-53	N/A	-114	N/A
6/30/2015	247	-48	N/A	-91	N/A
3/31/2015	240	-34	N/A	-78	N/A
12/31/2014	246	-19	N/A	-14	N/A
9/30/2014	256	1	N/A	-27	N/A
6/30/2014	247	3	N/A	-10	N/A
3/31/2014	244	7	N/A	-6	N/A
12/31/2013	233	3	N/A	-22	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if 1783's forecast earnings growth is above the savings rate (1%).

Earnings vs Market: Insufficient data to determine if 1783's earnings are forecast to grow faster than the TW market

High Growth Earnings: Insufficient data to determine if 1783's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if 1783's revenue is forecast to grow faster than the TW market.

High Growth Revenue: Insufficient data to determine if 1783's revenue is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if 1783's Return on Equity is forecast to be high in 3 years time

Maxigen Biotech Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Recent updates

Second quarter 2024 earnings released: EPS: NT$0.66 (vs NT$0.70 in 2Q 2023)

Maxigen Biotech Inc. to Report Q2, 2024 Results on Jul 29, 2024

Upcoming dividend of NT$1.00 per share

New minor risk - Dividend sustainability

First quarter 2024 earnings released: EPS: NT$0.32 (vs NT$0.50 in 1Q 2023)

Maxigen Biotech Inc. to Report Q1, 2024 Results on May 03, 2024

Maxigen Biotech's (TWSE:1783) Earnings Are Of Questionable Quality

Full year 2023 earnings released: EPS: NT$1.86 (vs NT$1.57 in FY 2022)

Maxigen Biotech Inc., Annual General Meeting, Jun 13, 2024

Now 21% undervalued after recent price drop

Upcoming dividend of NT$0.50 per share at 0.9% yield

Maxigen Biotech Inc. Declares Dividend, Payable on October 12, 2023

Now 21% undervalued after recent price drop

Second quarter 2023 earnings released: EPS: NT$0.74 (vs NT$0.40 in 2Q 2022)

Now 21% undervalued

Maxigen Biotech Inc. Announces Cash Dividend for the Period from January 1, 2022 to December 31, 2022

Investor sentiment improves as stock rises 16%

Full year 2022 earnings released: EPS: NT$1.65 (vs NT$1.10 in FY 2021)

Investor sentiment improves as stock rises 16%

Maxigen Biotech Inc. Announces Resignation of You Wan-How as Financial Officer and Accounting Officer

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: NT$0.55 (vs NT$0.42 in 3Q 2021)

Second quarter 2022 earnings released: EPS: NT$0.43 (vs NT$0.31 in 2Q 2021)

Investor sentiment improved over the past week

Maxigen Biotech Inc. Announces Resignation of Lu Min Hsuan as Chief Internal Auditor

First quarter 2022 earnings released: EPS: NT$0.27 (vs NT$0.31 in 1Q 2021)

Maxigen Biotech Inc. Appoints Lin Yung-Hsiang to Nomination Committee

Investor sentiment deteriorated over the past week

Less than half of directors are independent

Maxigen Biotech Inc., Annual General Meeting, Jun 21, 2022

Third quarter 2021 earnings released: EPS NT$0.42 (vs NT$0.18 in 3Q 2020)

Investor sentiment deteriorated over the past week

Second quarter 2021 earnings released: EPS NT$0.31 (vs NT$0.30 in 2Q 2020)

Upcoming dividend of NT$0.73 per share

Investor sentiment improved over the past week

First quarter 2021 earnings released: EPS NT$0.31 (vs NT$0.15 in 1Q 2020)

Maxigen Biotech Inc. (TPE:1783) Is Yielding 2.3% - But Is It A Buy?

We Think You Should Be Aware Of Some Concerning Factors In Maxigen Biotech's (TPE:1783) Earnings

Full year 2020 earnings released: EPS NT$0.91 (vs NT$0.86 in FY 2019)

Maxigen Biotech Inc.'s (TPE:1783) Stock Has Seen Strong Momentum: Does That Call For Deeper Study Of Its Financial Prospects?

Investor sentiment improved over the past week

The Maxigen Biotech (TPE:1783) Share Price Has Gained 22% And Shareholders Are Hoping For More

New 90-day high: NT$24.00

Can Maxigen Biotech (TPE:1783) Continue To Grow Its Returns On Capital?

Tread With Caution Around Maxigen Biotech Inc.'s (TPE:1783) 3.4% Dividend Yield

Declining Stock and Decent Financials: Is The Market Wrong About Maxigen Biotech Inc. (TPE:1783)?

If You Had Bought Maxigen Biotech's (TPE:1783) Shares Five Years Ago You Would Be Down 13%

Third quarter 2020 earnings released: EPS NT$0.18

New 90-day low: NT$22.15

New 90-day low: NT$23.05

New 90-day low - NT$23.15

First half earnings released

First half earnings released

Upcoming Dividend of NT$0.78 Per Share

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies